These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38480462)

  • 1. Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
    Woo HK; Park J; Kim KH; Ku JY; Ha HK; Cho YK
    Cancer Sci; 2024 May; 115(5):1602-1610. PubMed ID: 38480462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.
    Monypenny J; Milewicz H; Flores-Borja F; Weitsman G; Cheung A; Chowdhury R; Burgoyne T; Arulappu A; Lawler K; Barber PR; Vicencio JM; Keppler M; Wulaningsih W; Davidson SM; Fraternali F; Woodman N; Turmaine M; Gillett C; Franz D; Quezada SA; Futter CE; Von Kriegsheim A; Kolch W; Vojnovic B; Carlton JG; Ng T
    Cell Rep; 2018 Jul; 24(3):630-641. PubMed ID: 30021161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
    Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
    J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer cells synergistically defend against CD8
    Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
    Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
    Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
    ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
    de Jong JJ; Stoop H; Boormans JL; van Leenders GJLH
    Virchows Arch; 2021 Oct; 479(4):705-713. PubMed ID: 33909149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
    Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis.
    Liu C; Zeng X; An Z; Yang Y; Eisenbaum M; Gu X; Jornet JM; Dy GK; Reid ME; Gan Q; Wu Y
    ACS Sens; 2018 Aug; 3(8):1471-1479. PubMed ID: 30019892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
    Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
    Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application.
    Liu J; Qin J; Liang L; Zhang X; Gao J; Hao Y; Zhao P
    Eur J Pharmacol; 2024 Sep; 979():176831. PubMed ID: 39047964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
    Fan Y; Che X; Qu J; Hou K; Wen T; Li Z; Li C; Wang S; Xu L; Liu Y; Qu X
    Ann Surg Oncol; 2019 Oct; 26(11):3745-3755. PubMed ID: 31087180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.